Is Verastem, Inc. technically bullish or bearish?
2025-11-05 11:23:54As of 31 October 2025, the technical trend for Verastem, Inc. has changed from mildly bullish to bullish. The current stance is bullish, driven by the monthly MACD and KST indicators, both of which are bullish. Additionally, Bollinger Bands are bullish on both weekly and monthly time frames, and daily moving averages also indicate a bullish trend. However, the weekly MACD is mildly bearish, and Dow Theory shows a mixed signal with mildly bullish weekly and mildly bearish monthly indicators. In terms of performance, Verastem has outperformed the S&P 500 year-to-date with a return of 53.00% compared to 16.30%, and over the past year, it has significantly outperformed with a return of 101.79% against 19.89%....
Read More
Verastem, Inc. Experiences Revision in Stock Evaluation Amid Strong Market Performance
2025-11-04 16:00:03Verastem, Inc., a microcap in the Pharmaceuticals & Biotechnology sector, has seen significant stock performance, achieving a 152.55% return over the past year. The stock is currently priced at $9.90, reflecting notable volatility and a recovery trajectory amid mixed technical indicators and market dynamics.
Read More
Verastem, Inc. Experiences Evaluation Revision Amid Strong Market Performance and Volatility
2025-10-14 16:14:57Verastem, Inc., a microcap in the Pharmaceuticals & Biotechnology sector, has seen its stock price rise slightly to $9.29. Over the past year, it achieved a remarkable return of 211.74%, significantly outperforming the S&P 500. The company's performance reflects notable volatility and resilience in the market.
Read MoreIs Verastem, Inc. technically bullish or bearish?
2025-10-14 11:39:18As of 10 October 2025, the technical trend for Verastem, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The Bollinger Bands indicate a mildly bullish stance for both weekly and monthly periods. However, the weekly RSI is bearish, suggesting some weakness. Moving averages are mildly bullish on a daily basis. The KST is bullish for both weekly and monthly periods, while the Dow Theory shows a mildly bullish trend on the weekly timeframe. The OBV is mildly bearish on a weekly basis, indicating some selling pressure. In terms of performance, Verastem has significantly outperformed the S&P 500 year-to-date with a return of 79.69% compared to the S&P 500's 11.41%, and over the past year, it has returned 211.74% versus the S&P 500's 13.36%. Overall, the current technical stance is mildly bullish, driven by the mixed signals from MACD, Bolling...
Read MoreIs Verastem, Inc. technically bullish or bearish?
2025-10-13 11:41:05As of 10 October 2025, the technical trend for Verastem, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The Bollinger Bands indicate a mildly bullish stance on both weekly and monthly time frames. However, the weekly RSI is bearish, and the OBV shows a mildly bearish trend. The daily moving averages are mildly bullish, and the KST is bullish on both weekly and monthly time frames. In terms of performance, Verastem has outperformed the S&P 500 year-to-date with a return of 65.76% compared to the S&P 500's 11.41%, and over the past year, it has returned 187.58% against the S&P 500's 13.36%. Overall, the current technical stance is mildly bullish, driven primarily by the bullish MACD and KST indicators, despite some bearish signals from the RSI and OBV....
Read MoreIs Verastem, Inc. technically bullish or bearish?
2025-10-12 11:28:33As of 10 October 2025, the technical trend for Verastem, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The weekly RSI is bearish, but there is no signal on the monthly RSI. Bollinger Bands indicate a mildly bullish stance on both weekly and monthly time frames. Daily moving averages are also mildly bullish. The KST is bullish on both weekly and monthly charts, while the Dow Theory shows a mildly bullish trend on the weekly and no trend on the monthly. However, the OBV is mildly bearish on the weekly and shows no trend on the monthly. In terms of returns, Verastem has outperformed the S&P 500 significantly over the past year, with a return of 187.58% compared to the S&P 500's 13.36%, but it has underperformed over the last 5 years, with a return of -48.99% versus the S&P 500's 88.45%. Overall, the current technical stance is mildly bul...
Read MoreIs Verastem, Inc. technically bullish or bearish?
2025-09-20 19:50:15As of 25 August 2025, the technical trend for Verastem, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and the daily moving averages also indicate a bullish stance. The Bollinger Bands show a mildly bullish trend on the weekly and a bullish trend on the monthly. KST is bullish for both weekly and monthly periods, while the Dow Theory indicates a mildly bullish stance on the monthly but no trend on the weekly. In terms of performance, Verastem has significantly outperformed the S&P 500 across multiple periods, with a 1-year return of 252.03% compared to the S&P 500's 17.14%. Overall, the current technical stance is bullish with strong indicators supporting this view....
Read MoreIs Verastem, Inc. overvalued or undervalued?
2025-09-20 18:24:46As of 8 August 2024, the valuation grade for Verastem, Inc. has moved from does not qualify to risky, indicating a more cautious outlook. The company appears to be overvalued given its negative valuation ratios, including a Price to Book Value of -10.88 and an EV to EBITDA of -2.38. Additionally, the negative ROCE and ROE further underscore the challenges facing the company. In comparison to its peers, Verastem's P/E ratio is -4.0339, while Poseida Therapeutics, Inc. has a P/E of -15.2392 and MeiraGTx Holdings Plc stands at -3.8154, highlighting that Verastem is not the most attractive option within its sector. Despite recent strong returns, with a 1Y stock return of 252.03% compared to the S&P 500's 17.14%, the underlying valuation metrics suggest that caution is warranted....
Read More





